{ "run": { "id": "cmnr12z3102rip658aiwa11se", "region": "US", "assetId": "cmnr12z2r02rcp658f4otbh45", "ticker": "CI", "snapshotId": "cmnr12z2v02rep6588whko533", "promptTemplateId": "cmnqt07si0005lm3jzpxuu1ux", "createdAt": "2026-04-09T05:20:08.987Z", "promptTemplate": { "id": "cmnqt07si0005lm3jzpxuu1ux", "name": "Oficial 08.apr.2026", "version": 1 }, "snapshot": { "id": "cmnr12z2v02rep6588whko533", "assetId": "cmnr12z2r02rcp658f4otbh45", "asOf": "2026-04-08T20:00:02.000Z", "snapshot": { "asOf": "2026-04-08T20:00:02.000Z", "quote": { "asOf": "2026-04-08T20:00:02.000Z", "open": null, "price": 277.56, "dayLow": 272.475, "volume": 755816, "dayHigh": 277.79, "currency": "USD", "prevClose": 274.25, "week52Low": 239.51, "week52High": 350 }, "fundamentals": { "pe": 15.3825441039926, "beta": 0.954797670080983, "epsTTM": 21.54, "fcfTTM": 5637000000, "growth": { "epsYoy": 0.8228571428571427, "revenueYoy": 0.1124105195430578 }, "sector": "Hospital & Medical Service Plans", "margins": { "net": 0.02166969807202619, "gross": null, "operating": 0.03346671516915242 }, "website": "http://www.cignaglobalhealth.com/", "industry": null, "pegRatio": 0.430548456667305, "ebitdaTTM": 12833000000, "forwardPe": 13.5850758507585, "marketCap": 88000000000, "totalCash": 7676000000, "totalDebt": 31463000000, "debtEquity": 0.692926546621501, "quickRatio": 0.6655780767455894, "revenueTTM": 274900000000, "companyName": "Cigna Group", "priceToBook": 2.30852800503837, "currentRatio": 0.8486386709736964, "dividendYield": 0.013366015363594, "returnOnAssets": 0.03772187007263217, "returnOnEquity": 0.150338741308611, "analystOpinions": null, "businessSummary": "The Cigna Group is an American multinational for-profit managed healthcare and insurance company based in Bloomfield, Connecticut. Cigna's insurance subsidiaries are major providers of medical, dental, disability, life and accident insurance and related products and services, the majority of which are offered through employers and other groups (e.g., governmental and non-governmental organizations, unions and associations).", "enterpriseValue": 128939642354.48, "analystTargetLow": null, "analystTargetHigh": null, "analystTargetMean": null, "fullTimeEmployees": 73500, "sharesOutstanding": 263528277, "enterpriseToEbitda": 10.04750583296813, "analystTargetMedian": null, "enterpriseToRevenue": 0.4690419874662786, "operatingCashflowTTM": 9601000000, "analystRecommendationKey": null } }, "createdAt": "2026-04-09T05:20:08.983Z" }, "results": [ { "id": "cmnr12z3802rkp658fhuefpgr", "runId": "cmnr12z3102rip658aiwa11se", "modelId": "anthropic", "status": "SUCCESS", "rawOutput": "{\"model\":\"ai-equity-research-v1\",\"as_of\":\"2026-04-08T20:00:02.000Z\",\"ticker\":\"CI\",\"currency\":\"USD\",\"current_price\":277.56,\"target_price_6m\":298,\"target_price_12m\":315,\"recommendation\":\"BUY\",\"confidence\":0.68,\"thesis_bullets\":[\"Trades at 13.6x forward P/E, well below 52-week high of $350.\",\"PEG ratio of 0.43 signals undervaluation relative to earnings growth.\",\"Strong FCF generation of $5.6B supports buybacks and dividends.\",\"Evernorth services diversification reduces pure insurance risk.\",\"ROE of 15% with manageable 0.69x debt-to-equity supports capital returns.\"],\"key_drivers\":[{\"driver\":\"Evernorth PBM and specialty pharmacy revenue growth\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Medical cost ratio trend / utilization normalization\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Share buyback program reducing float\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Medicare Advantage and government segment expansion\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"GLP-1 drug cost management and formulary negotiations\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"PBM regulatory and transparency scrutiny\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Operating margin improvement toward 3.5-4%\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Interest expense from $31.5B debt load\",\"impact\":\"LOW\",\"direction\":\"NEG\"}],\"risks\":[\"PBM reform legislation could compress Evernorth margins significantly.\",\"Medical loss ratio deterioration from rising healthcare utilization.\",\"GLP-1 and specialty drug cost inflation outpacing premium increases.\",\"Potential Medicaid redetermination impact on membership volumes.\",\"Macro recession risk reducing employer-sponsored coverage enrollment.\"],\"assumptions\":{\"revenue_cagr_3y\":0.07,\"ebit_margin_target\":0.038,\"wacc\":0.095,\"terminal_multiple\":14},\"scenarios\":{\"bear\":{\"target_price\":240,\"prob\":0.2,\"notes\":\"PBM regulation tightens margins; elevated MLR compresses earnings to ~$18 EPS at 13x.\"},\"base\":{\"target_price\":315,\"prob\":0.55,\"notes\":\"Steady EPS growth to ~$23; moderate multiple expansion to ~14x forward P/E.\"},\"bull\":{\"target_price\":370,\"prob\":0.25,\"notes\":\"Strong Evernorth growth and buybacks drive EPS to ~$25; re-rate to 15x.\"}},\"method_notes\":\"Earnings-power valuation anchored on forward P/E for managed care. TTM EPS $21.54 with 82% YoY growth (partially non-recurring); normalized forward EPS ~$20-22 growing to ~$23 in 12M via organic growth + buybacks. Applied 13.5-14x P/E range vs peers. 12M expected return ~13.5% supports BUY. PEG of 0.43 corroborates value. Key risk is PBM regulatory overhang capping multiple. Not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "ai-equity-research-v1", "risks": [ "PBM reform legislation could compress Evernorth margins significantly.", "Medical loss ratio deterioration from rising healthcare utilization.", "GLP-1 and specialty drug cost inflation outpacing premium increases.", "Potential Medicaid redetermination impact on membership volumes.", "Macro recession risk reducing employer-sponsored coverage enrollment." ], "ticker": "CI", "currency": "USD", "scenarios": { "base": { "prob": 0.55, "notes": "Steady EPS growth to ~$23; moderate multiple expansion to ~14x forward P/E.", "target_price": 315 }, "bear": { "prob": 0.2, "notes": "PBM regulation tightens margins; elevated MLR compresses earnings to ~$18 EPS at 13x.", "target_price": 240 }, "bull": { "prob": 0.25, "notes": "Strong Evernorth growth and buybacks drive EPS to ~$25; re-rate to 15x.", "target_price": 370 } }, "confidence": 0.68, "assumptions": { "wacc": 0.095, "revenue_cagr_3y": 0.07, "terminal_multiple": 14, "ebit_margin_target": 0.038 }, "key_drivers": [ { "driver": "Evernorth PBM and specialty pharmacy revenue growth", "impact": "HIGH", "direction": "POS" }, { "driver": "Medical cost ratio trend / utilization normalization", "impact": "HIGH", "direction": "NEG" }, { "driver": "Share buyback program reducing float", "impact": "MED", "direction": "POS" }, { "driver": "Medicare Advantage and government segment expansion", "impact": "MED", "direction": "POS" }, { "driver": "GLP-1 drug cost management and formulary negotiations", "impact": "HIGH", "direction": "NEG" }, { "driver": "PBM regulatory and transparency scrutiny", "impact": "MED", "direction": "NEG" }, { "driver": "Operating margin improvement toward 3.5-4%", "impact": "MED", "direction": "POS" }, { "driver": "Interest expense from $31.5B debt load", "impact": "LOW", "direction": "NEG" } ], "method_notes": "Earnings-power valuation anchored on forward P/E for managed care. TTM EPS $21.54 with 82% YoY growth (partially non-recurring); normalized forward EPS ~$20-22 growing to ~$23 in 12M via organic growth + buybacks. Applied 13.5-14x P/E range vs peers. 12M expected return ~13.5% supports BUY. PEG of 0.43 corroborates value. Key risk is PBM regulatory overhang capping multiple. Not investment advice.", "current_price": 277.56, "recommendation": "BUY", "thesis_bullets": [ "Trades at 13.6x forward P/E, well below 52-week high of $350.", "PEG ratio of 0.43 signals undervaluation relative to earnings growth.", "Strong FCF generation of $5.6B supports buybacks and dividends.", "Evernorth services diversification reduces pure insurance risk.", "ROE of 15% with manageable 0.69x debt-to-equity supports capital returns." ], "target_price_6m": 298, "target_price_12m": 315 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "anthropic", "webSearch": { "enabled": false, "maxToolCalls": 2, "disabledReason": null }, "pauseTurns": 0, "stopReason": "end_turn" }, "sanityIssues": [] }, "latencyMs": 37848, "createdAt": "2026-04-09T05:20:08.987Z", "usage": { "inputTokens": 3592, "outputTokens": 1724, "costUsd": 0.06106 } }, { "id": "cmnr12z3802rnp6586b2kfk94", "runId": "cmnr12z3102rip658aiwa11se", "modelId": "deepseek.reasoner", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI Equity Research Model\",\n \"as_of\": \"2026-04-08T20:00:02.000Z\",\n \"ticker\": \"CI\",\n \"currency\": \"USD\",\n \"current_price\": 277.56,\n \"target_price_6m\": 290.0,\n \"target_price_12m\": 305.0,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.7,\n \"thesis_bullets\": [\n \"Strong revenue growth driven by healthcare demand.\",\n \"Improving operating margins through cost efficiencies.\",\n \"Stable cash flow generation supporting dividends.\",\n \"Regulatory environment poses ongoing risks.\",\n \"Valuation reasonable with upside potential.\"\n ],\n \"key_drivers\": [\n { \"driver\": \"Healthcare insurance premium growth\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n { \"driver\": \"Medical cost inflation\", \"impact\": \"HIGH\", \"direction\": \"NEG\" },\n { \"driver\": \"Regulatory changes\", \"impact\": \"MED\", \"direction\": \"NEG\" },\n { \"driver\": \"Competition in managed care\", \"impact\": \"MED\", \"direction\": \"NEG\" },\n { \"driver\": \"EPS growth from operational improvements\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n { \"driver\": \"Debt management and interest rates\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"Market share gains\", \"impact\": \"LOW\", \"direction\": \"POS\" },\n { \"driver\": \"Economic cycles affecting employment\", \"impact\": \"MED\", \"direction\": \"NEG\" }\n ],\n \"risks\": [\n \"Regulatory overhaul in healthcare.\",\n \"Rising medical costs outpacing premiums.\",\n \"Economic downturn reducing employer-based coverage.\",\n \"Increased competition.\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.06,\n \"ebit_margin_target\": 0.035,\n \"wacc\": 0.07,\n \"terminal_multiple\": 15.0\n },\n \"scenarios\": {\n \"bear\": { \"target_price\": 260.0, \"prob\": 0.2, \"notes\": \"Lower growth and multiple compression.\" },\n \"base\": { \"target_price\": 305.0, \"prob\": 0.6, \"notes\": \"Steady execution on current plans.\" },\n \"bull\": { \"target_price\": 340.0, \"prob\": 0.2, \"notes\": \"Faster growth and margin expansion.\" }\n },\n \"method_notes\": \"Valuation based on earnings growth and peer multiples. Recommendation reflects upside potential with balanced risks. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "AI Equity Research Model", "risks": [ "Regulatory overhaul in healthcare.", "Rising medical costs outpacing premiums.", "Economic downturn reducing employer-based coverage.", "Increased competition." ], "ticker": "CI", "currency": "USD", "scenarios": { "base": { "prob": 0.6, "notes": "Steady execution on current plans.", "target_price": 305 }, "bear": { "prob": 0.2, "notes": "Lower growth and multiple compression.", "target_price": 260 }, "bull": { "prob": 0.2, "notes": "Faster growth and margin expansion.", "target_price": 340 } }, "confidence": 0.7, "assumptions": { "wacc": 0.07, "revenue_cagr_3y": 0.06, "terminal_multiple": 15, "ebit_margin_target": 0.035 }, "key_drivers": [ { "driver": "Healthcare insurance premium growth", "impact": "HIGH", "direction": "POS" }, { "driver": "Medical cost inflation", "impact": "HIGH", "direction": "NEG" }, { "driver": "Regulatory changes", "impact": "MED", "direction": "NEG" }, { "driver": "Competition in managed care", "impact": "MED", "direction": "NEG" }, { "driver": "EPS growth from operational improvements", "impact": "HIGH", "direction": "POS" }, { "driver": "Debt management and interest rates", "impact": "MED", "direction": "POS" }, { "driver": "Market share gains", "impact": "LOW", "direction": "POS" }, { "driver": "Economic cycles affecting employment", "impact": "MED", "direction": "NEG" } ], "method_notes": "Valuation based on earnings growth and peer multiples. Recommendation reflects upside potential with balanced risks. Not investment advice.", "current_price": 277.56, "recommendation": "BUY", "thesis_bullets": [ "Strong revenue growth driven by healthcare demand.", "Improving operating margins through cost efficiencies.", "Stable cash flow generation supporting dividends.", "Regulatory environment poses ongoing risks.", "Valuation reasonable with upside potential." ], "target_price_6m": 290, "target_price_12m": 305 }, "errorsJson": { "attempts": [], "providerMeta": { "endpoint": "https://api.deepseek.com/v1/chat/completions", "provider": "deepseek", "webSearch": { "enabled": false, "supported": false }, "responseFormat": "json_object" }, "sanityIssues": [] }, "latencyMs": 348, "createdAt": "2026-04-09T05:20:08.987Z", "usage": { "inputTokens": 2103, "outputTokens": 3891, "costUsd": 0.002223 } }, { "id": "cmnr12z3802rlp658qgg49xqd", "runId": "cmnr12z3102rip658aiwa11se", "modelId": "gemini.3-pro", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"EquityResearch-AlphaGen\",\n \"as_of\": \"2026-04-08T20:00:02.000Z\",\n \"ticker\": \"CI\",\n \"currency\": \"USD\",\n \"current_price\": 277.56,\n \"target_price_6m\": 295.00,\n \"target_price_12m\": 315.00,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.70,\n \"thesis_bullets\": [\n \"Evernorth's specialty pharmacy growth provides a durable, high-margin revenue stream offsetting traditional insurance risks.\",\n \"Valuation is attractive at ~13.6x forward earnings, below historical averages for managed care peers.\",\n \"Strong free cash flow generation of $5.6B supports aggressive share repurchases and dividend growth.\",\n \"Regulatory scrutiny on PBM pricing models remains a persistent overhang on multiple expansion.\",\n \"Medical cost trend normalization poses near-term risks to Cigna Healthcare's operating margins.\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Evernorth Revenue Growth\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Medical Care Ratio (MCR) Trends\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"PBM Regulatory Legislation\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Share Repurchase Program\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Medicare Advantage Rates\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Specialty Pharmacy Margins\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Commercial Enrollment Growth\",\n \"impact\": \"LOW\",\n \"direction\": \"POS\"\n }\n ],\n \"risks\": [\n \"Legislative action targeting PBM spread pricing and rebate retention.\",\n \"Unexpected spikes in medical utilization driving up the Medical Care Ratio (MCR).\",\n \"Increased competition in the specialty pharmacy and behavioral health markets.\",\n \"Integration risks or overpayment for future bolt-on acquisitions.\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.08,\n \"ebit_margin_target\": 0.045,\n \"wacc\": 0.075,\n \"terminal_multiple\": 12.5\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 230.00,\n \"prob\": 0.25,\n \"notes\": \"Regulatory pressures on PBMs and higher medical loss ratios compress margins.\"\n },\n \"base\": {\n \"target_price\": 315.00,\n \"prob\": 0.55,\n \"notes\": \"Steady growth in Evernorth and stable MCR drive ~14% upside.\"\n },\n \"bull\": {\n \"target_price\": 360.00,\n \"prob\": 0.20,\n \"notes\": \"Strong margin expansion in Evernorth and accretive capital deployment.\"\n }\n },\n \"method_notes\": \"Blended valuation using 10-year DCF (7.5% WACC, 2% terminal growth) and forward P/E multiple of 14.5x. Buy recommendation reflects ~13.5% upside to base case, supported by strong FCF and Evernorth growth, balanced against PBM regulatory risks. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "EquityResearch-AlphaGen", "risks": [ "Legislative action targeting PBM spread pricing and rebate retention.", "Unexpected spikes in medical utilization driving up the Medical Care Ratio (MCR).", "Increased competition in the specialty pharmacy and behavioral health markets.", "Integration risks or overpayment for future bolt-on acquisitions." ], "ticker": "CI", "currency": "USD", "scenarios": { "base": { "prob": 0.55, "notes": "Steady growth in Evernorth and stable MCR drive ~14% upside.", "target_price": 315 }, "bear": { "prob": 0.25, "notes": "Regulatory pressures on PBMs and higher medical loss ratios compress margins.", "target_price": 230 }, "bull": { "prob": 0.2, "notes": "Strong margin expansion in Evernorth and accretive capital deployment.", "target_price": 360 } }, "confidence": 0.7, "assumptions": { "wacc": 0.075, "revenue_cagr_3y": 0.08, "terminal_multiple": 12.5, "ebit_margin_target": 0.045 }, "key_drivers": [ { "driver": "Evernorth Revenue Growth", "impact": "HIGH", "direction": "POS" }, { "driver": "Medical Care Ratio (MCR) Trends", "impact": "HIGH", "direction": "NEG" }, { "driver": "PBM Regulatory Legislation", "impact": "HIGH", "direction": "NEG" }, { "driver": "Share Repurchase Program", "impact": "MED", "direction": "POS" }, { "driver": "Medicare Advantage Rates", "impact": "MED", "direction": "NEG" }, { "driver": "Specialty Pharmacy Margins", "impact": "MED", "direction": "POS" }, { "driver": "Commercial Enrollment Growth", "impact": "LOW", "direction": "POS" } ], "method_notes": "Blended valuation using 10-year DCF (7.5% WACC, 2% terminal growth) and forward P/E multiple of 14.5x. Buy recommendation reflects ~13.5% upside to base case, supported by strong FCF and Evernorth growth, balanced against PBM regulatory risks. Not investment advice.", "current_price": 277.56, "recommendation": "BUY", "thesis_bullets": [ "Evernorth's specialty pharmacy growth provides a durable, high-margin revenue stream offsetting traditional insurance risks.", "Valuation is attractive at ~13.6x forward earnings, below historical averages for managed care peers.", "Strong free cash flow generation of $5.6B supports aggressive share repurchases and dividend growth.", "Regulatory scrutiny on PBM pricing models remains a persistent overhang on multiple expansion.", "Medical cost trend normalization poses near-term risks to Cigna Healthcare's operating margins." ], "target_price_6m": 295, "target_price_12m": 315 }, "errorsJson": { "attempts": [], "providerMeta": { "model": "gemini-3-pro-preview", "provider": "gemini", "webSearch": { "used": false, "allowed": false, "enabled": false, "requested": false, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 22924, "createdAt": "2026-04-09T05:20:08.987Z", "usage": { "inputTokens": 2467, "outputTokens": 905, "costUsd": 0.015794 } }, { "id": "cmnr12z3802rjp658r7tt66ly", "runId": "cmnr12z3102rip658aiwa11se", "modelId": "openai.gpt-5.4", "status": "SUCCESS", "rawOutput": "{\"model\":\"AI Model Recommendation v2\",\"as_of\":\"2026-04-08T20:00:02.000Z\",\"ticker\":\"CI\",\"currency\":\"USD\",\"current_price\":277.56,\"target_price_6m\":292,\"target_price_12m\":305,\"recommendation\":\"BUY\",\"confidence\":0.62,\"thesis_bullets\":[\"Low-teens earnings multiple underprices durable cash flow and capital return capacity.\",\"Medicare divestiture should improve mix quality and reduce government-program volatility.\",\"Evernorth scale and client stickiness support earnings despite ongoing PBM scrutiny.\",\"Strong free cash flow enables buybacks, debt service, and selective reinvestment.\",\"Regulatory risk and medical-cost pressure likely limit valuation upside to moderate levels.\"],\"key_drivers\":[{\"driver\":\"Capital return and buybacks\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Medicare divestiture mix shift\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Evernorth retention and pricing\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Medical cost trend\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"PBM regulation and rebate reform\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Commercial enrollment and rate actions\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Debt reduction and cash conversion\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Litigation and policy shocks\",\"impact\":\"MED\",\"direction\":\"NEG\"}],\"risks\":[\"PBM regulation compresses Evernorth margins.\",\"Higher medical utilization hurts Cigna Healthcare profitability.\",\"Large-client losses or pricing pressure reduce earnings visibility.\",\"Capital deployment or M&A missteps dilute returns.\",\"Policy changes increase compliance costs and volatility.\"],\"assumptions\":{\"revenue_cagr_3y\":0.045,\"ebit_margin_target\":0.038,\"wacc\":0.085,\"terminal_multiple\":10.8},\"scenarios\":{\"bear\":{\"target_price\":245,\"prob\":0.25,\"notes\":\"PBM reform and utilization pressure keep the multiple compressed.\"},\"base\":{\"target_price\":305,\"prob\":0.55,\"notes\":\"Steady execution and buybacks drive modest rerating.\"},\"bull\":{\"target_price\":345,\"prob\":0.2,\"notes\":\"Smooth divestiture, strong retention, and capital returns lift EPS faster.\"}},\"method_notes\":\"Base case uses blended earnings-power and EV/EBITDA valuation from snapshot cash flow, leverage and margins; upside comes from buybacks and cleaner post-divestiture mix, while PBM/utilization risks cap rerating. I did not use sell-side targets. Snapshot PE is internally inconsistent with price/EPS. not investment advice\"}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "AI Model Recommendation v2", "risks": [ "PBM regulation compresses Evernorth margins.", "Higher medical utilization hurts Cigna Healthcare profitability.", "Large-client losses or pricing pressure reduce earnings visibility.", "Capital deployment or M&A missteps dilute returns.", "Policy changes increase compliance costs and volatility." ], "ticker": "CI", "currency": "USD", "scenarios": { "base": { "prob": 0.55, "notes": "Steady execution and buybacks drive modest rerating.", "target_price": 305 }, "bear": { "prob": 0.25, "notes": "PBM reform and utilization pressure keep the multiple compressed.", "target_price": 245 }, "bull": { "prob": 0.2, "notes": "Smooth divestiture, strong retention, and capital returns lift EPS faster.", "target_price": 345 } }, "confidence": 0.62, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.045, "terminal_multiple": 10.8, "ebit_margin_target": 0.038 }, "key_drivers": [ { "driver": "Capital return and buybacks", "impact": "HIGH", "direction": "POS" }, { "driver": "Medicare divestiture mix shift", "impact": "HIGH", "direction": "POS" }, { "driver": "Evernorth retention and pricing", "impact": "HIGH", "direction": "POS" }, { "driver": "Medical cost trend", "impact": "HIGH", "direction": "NEG" }, { "driver": "PBM regulation and rebate reform", "impact": "HIGH", "direction": "NEG" }, { "driver": "Commercial enrollment and rate actions", "impact": "MED", "direction": "POS" }, { "driver": "Debt reduction and cash conversion", "impact": "MED", "direction": "POS" }, { "driver": "Litigation and policy shocks", "impact": "MED", "direction": "NEG" } ], "method_notes": "Base case uses blended earnings-power and EV/EBITDA valuation from snapshot cash flow, leverage and margins; upside comes from buybacks and cleaner post-divestiture mix, while PBM/utilization risks cap rerating. I did not use sell-side targets. Snapshot PE is internally inconsistent with price/EPS. not investment advice", "current_price": 277.56, "recommendation": "BUY", "thesis_bullets": [ "Low-teens earnings multiple underprices durable cash flow and capital return capacity.", "Medicare divestiture should improve mix quality and reduce government-program volatility.", "Evernorth scale and client stickiness support earnings despite ongoing PBM scrutiny.", "Strong free cash flow enables buybacks, debt service, and selective reinvestment.", "Regulatory risk and medical-cost pressure likely limit valuation upside to moderate levels." ], "target_price_6m": 292, "target_price_12m": 305 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "openai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "resp_02307aff889a62d60069d75725c6e48193bd36b7c45764ae82", "reasoningEffort": "medium", "structuredOutputs": { "used": true, "requested": true, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 52973, "createdAt": "2026-04-09T05:20:08.987Z", "usage": { "inputTokens": 2375, "outputTokens": 2899, "costUsd": 0.044742 } }, { "id": "cmnr12z3802rmp658vn8mpowu", "runId": "cmnr12z3102rip658aiwa11se", "modelId": "xai.grok-4.20-reasoning", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI Equity Analyst\",\n \"as_of\": \"2026-04-08T20:00:02.000Z\",\n \"ticker\": \"CI\",\n \"currency\": \"USD\",\n \"current_price\": 277.56,\n \"target_price_6m\": 295,\n \"target_price_12m\": 320,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.62,\n \"thesis_bullets\": [\n \"11% revenue growth and 82% EPS rise show strong momentum\",\n \"Forward P/E 13.6 and PEG 0.43 indicate undervaluation\",\n \"Solid cash flow supports dividends and balance sheet strength\",\n \"Specialty services expansion diversifies revenue streams\",\n \"Regulatory shifts and cost inflation remain key headwinds\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Medical cost ratio trends\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Aging population healthcare demand\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"ACA and Medicare policy changes\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Acquisition integration synergies\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Operational efficiency improvements\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Competitive pricing in insurance\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Utilization rate normalization\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Specialty pharmacy growth\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n }\n ],\n \"risks\": [\n \"Rising healthcare costs outpacing premiums\",\n \"Adverse regulatory or ACA changes\",\n \"Intense competition from peers\",\n \"Acquisition integration failures\",\n \"Economic slowdown reducing enrollment\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.085,\n \"ebit_margin_target\": 0.05,\n \"wacc\": 0.085,\n \"terminal_multiple\": 12\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 235,\n \"prob\": 0.3,\n \"notes\": \"Higher medical loss ratios and regulatory tightening reduce earnings.\"\n },\n \"base\": {\n \"target_price\": 320,\n \"prob\": 0.5,\n \"notes\": \"Steady premium growth and margin stability align with guidance.\"\n },\n \"bull\": {\n \"target_price\": 375,\n \"prob\": 0.2,\n \"notes\": \"Superior cost control and market share gains accelerate profits.\"\n }\n },\n \"method_notes\": \"DCF using 8.5% revenue CAGR, 8.5% WACC and 12x terminal. 15% base upside supports BUY per rubric vs peers. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "AI Equity Analyst", "risks": [ "Rising healthcare costs outpacing premiums", "Adverse regulatory or ACA changes", "Intense competition from peers", "Acquisition integration failures", "Economic slowdown reducing enrollment" ], "ticker": "CI", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Steady premium growth and margin stability align with guidance.", "target_price": 320 }, "bear": { "prob": 0.3, "notes": "Higher medical loss ratios and regulatory tightening reduce earnings.", "target_price": 235 }, "bull": { "prob": 0.2, "notes": "Superior cost control and market share gains accelerate profits.", "target_price": 375 } }, "confidence": 0.62, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.085, "terminal_multiple": 12, "ebit_margin_target": 0.05 }, "key_drivers": [ { "driver": "Medical cost ratio trends", "impact": "HIGH", "direction": "NEG" }, { "driver": "Aging population healthcare demand", "impact": "HIGH", "direction": "POS" }, { "driver": "ACA and Medicare policy changes", "impact": "MED", "direction": "NEG" }, { "driver": "Acquisition integration synergies", "impact": "MED", "direction": "POS" }, { "driver": "Operational efficiency improvements", "impact": "HIGH", "direction": "POS" }, { "driver": "Competitive pricing in insurance", "impact": "MED", "direction": "NEG" }, { "driver": "Utilization rate normalization", "impact": "HIGH", "direction": "NEG" }, { "driver": "Specialty pharmacy growth", "impact": "MED", "direction": "POS" } ], "method_notes": "DCF using 8.5% revenue CAGR, 8.5% WACC and 12x terminal. 15% base upside supports BUY per rubric vs peers. Not investment advice.", "current_price": 277.56, "recommendation": "BUY", "thesis_bullets": [ "11% revenue growth and 82% EPS rise show strong momentum", "Forward P/E 13.6 and PEG 0.43 indicate undervaluation", "Solid cash flow supports dividends and balance sheet strength", "Specialty services expansion diversifies revenue streams", "Regulatory shifts and cost inflation remain key headwinds" ], "target_price_6m": 295, "target_price_12m": 320 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "xai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "082437f1-18ba-9215-876f-6cf3f42d1780", "usedFallbackChatCompletions": false }, "sanityIssues": [] }, "latencyMs": 16864, "createdAt": "2026-04-09T05:20:08.987Z", "usage": { "inputTokens": 2714, "outputTokens": 2644, "costUsd": 0.047802 } } ] } }